

**REMARKS**

Reconsideration of this application is requested.

With entry of this amendment, the pending claims are claims 1-14, 17-20, 24, 25, 27, 29, 30, 32, 33, 34 and 37. Of these claims, claims 10, 11, 24, 25, 27, 34 and 37 stand withdrawn although it is thought that, if applicants' main claim 1 is allowed, claims 10 and 11 should be included therewith.

Claim 1 has been amended to highlight novel and patentable aspects of the applicants' invention. Basis for the amendments to claim 1 is found at, for example, page 9, lines 4-5 and page 10, the 3rd paragraph of the applicants' disclosure.

Method claims 17-20 have been converted to composition claims dependent directly or indirectly on claim 1.

Claim 21 has been canceled as the feature thereof has been added to claim 1.

In view of the foregoing amendments, the Examiner is requested to reconsider the Section 102(b) rejection of the applicants' claims as anticipated by Janion et al. The reference does not disclose a pharmaceutical composition as defined by the applicants' claims, i.e. a composition in unitary dosage form comprising a virally-effective amount of a compound as defined. Accordingly, it is requested that the rejection based on Janion be withdrawn.

It is further noted that composition features of applicants' dependent claims are also not disclosed or suggested by Janion. Note, for example, the features of amended claims 17-20.


For generally similar reasons, the Examiner is requested to reconsider the Section 103(a) rejection based on Knutsen et al. The reference does not disclose or suggest pharmaceutical compositions as called for in the applicants' claims.

The Puglieses reference, applied with Knutsen et al. against claims 18-20, does not fill in the substantive deficiencies of Knutsen et al., as noted above.

Consistent with the foregoing, the applicants submit that their claims define patentable subject matter and should be allowed.

Favorable action is requested.

Respectfully submitted,  
MORGAN LEWIS & BOCKIUS LLP

By   
Paul N. Kokulis  
Reg. No. 16773

Date: July 28, 2008

**Customer No. 09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Phone: (202) 739-3000  
Facsimile: (202) 739-3001  
Direct: (202) 739-5455